Search Results - "Krebs, M. G."

Genomic context of NTRK1/2/3 fusion-positive tumours from a large real-world population by Westphalen, C. B., Krebs, M. G., Le Tourneau, C., Sokol, E. S., Maund, S. L., Wilson, T. R., Jin, D. X., Newberg, J. Y., Fabrizio, D., Veronese, L., Thomas, M., de Braud, F.

“…Neurotrophic tropomyosin receptor kinase ( NTRK) gene fusions are rare oncogenic drivers in solid tumours. This study aimed to interrogate a large real-world…”
Get full text

Social determinants of health inequalities in early phase clinical trials in Northern England by Rae, S., Shaya, S., Taylor, E., Hoben, J., Oluwashegun, D., Lowe, H., Haris, N., Bashir, S., Oing, C., Krebs, M. G., Thistlethwaite, F. C., Carter, L., Cook, N., Greystoke, A., Graham, D. M., Plummer, R.

“…Background Early phase clinical trials in Oncology represent a subspecialised area where UK patient selection is influenced by access to Experimental Cancer…”
Get full text

Author Correction: Genomic context of NTRK1/2/3 fusion-positive tumours from a large real-world population by Westphalen, C. B., Krebs, M. G., Le Tourneau, C., Sokol, E. S., Maund, S. L., Wilson, T. R., Jin, D. X., Newberg, J. Y., Fabrizio, D., Veronese, L., Thomas, M., de Braud, F.

Get full text

EPAC-lung: pooled analysis of circulating tumour cells in advanced non-small cell lung cancer by Lindsay, C.R., Blackhall, F.H., Carmel, A., Fernandez-Gutierrez, F., Gazzaniga, P., Groen, H.J.M., Hiltermann, T.J.N., Krebs, M.G., Loges, S., López-López, R., Muinelo-Romay, L., Pantel, K., Priest, L., Riethdorf, S., Rossi, E., Terstappen, L., Wikman, H., Soria, J.-C., Farace, F., Renehan, A., Dive, C., Besse, B., Michiels, S.

“…We assessed the clinical validity of circulating tumour cell (CTC) quantification for prognostication of patients with advanced non-small cell lung cancer…”
Get full text

TARGET National: A UK-wide Liquid-based Molecular Profiling Programme: On Behalf of the TARGET National Consortium by Ortega-Franco, A., Darlington, E., Greystoke, A., Krebs, M.G.

Get full text

The paradox-breaking panRAF plus SRC family kinase inhibitor, CCT3833, is effective in mutant KRAS-driven cancers by Saturno, G., Lopes, F., Niculescu-Duvaz, I., Niculescu-Duvaz, D., Zambon, A., Davies, L., Johnson, L., Preece, N., Lee, R., Viros, A., Holovanchuk, D., Pedersen, M., McLeary, R., Lorigan, P., Dhomen, N., Fisher, C., Banerji, U., Dean, E., Krebs, M.G., Gore, M., Larkin, J., Marais, R., Springer, C.

“…KRAS is mutated in ∼90% of pancreatic ductal adenocarcinomas, ∼35% of colorectal cancers and ∼20% of non-small-cell lung cancers. There has been recent…”
Get full text

Response to comment on “Intrapatient comparisons of efficacy in a single-arm trial of entrectinib in tumour-agnostic indications” by Krebs, M.G., Bennett, I.

Get full text

Vistusertib (dual m-TORC1/2 inhibitor) in combination with paclitaxel in patients with high-grade serous ovarian and squamous non-small-cell lung cancer by Basu, B., Krebs, M.G., Sundar, R., Wilson, R.H., Spicer, J., Jones, R., Brada, M., Talbot, D.C., Steele, N., Ingles Garces, A.H., Brugger, W., Harrington, E.A., Evans, J., Hall, E., Tovey, H., de Oliveira, F.M., Carreira, S., Swales, K., Ruddle, R., Raynaud, F.I., Purchase, B., Dawes, J.C., Parmar, M., Turner, A.J., Tunariu, N., Banerjee, S., de Bono, J.S., Banerji, U.

“…We have previously shown that raised p-S6K levels correlate with resistance to chemotherapy in ovarian cancer. We hypothesised that inhibiting p-S6K signalling…”
Get full text

Intrapatient comparisons of efficacy in a single-arm trial of entrectinib in tumour-agnostic indications by Krebs, M.G., Blay, J.-Y., Le Tourneau, C., Hong, D., Veronese, L., Antoniou, M., Bennett, I.

“…Entrectinib is a tropomyosin receptor kinase inhibitor approved for the treatment of neurotrophic tyrosine receptor kinase (NTRK) fusion-positive solid tumours…”
Get full text

Entrectinib in locally advanced or metastatic ROS1 fusion-positive non-small cell lung cancer (NSCLC): Integrated analysis of ALKA-372-001, STARTRK-1 and STARTRK-2 by Barlesi, F., Drilon, A., De Braud, F., Cho, B.C., Ahn, M.J., Siena, S., Krebs, M.G., Lin, C.C., John, T., Tan, D.S.W., Seto, T., Dziadziuszko, R., Arkenau, H.-T., Rolfo, C., Wolf, J., Ye, C., Riehl, T., Eng, S., Doebele, R.C.

Get full text

EPAC-Lung: Pooled analysis of circulating tumor cells in advanced non-small cell lung cancer by Lindsay, C.R., Blackhall, F.H., Carmel, A., Gazzaniga, P., Groen, H.J.M., Krebs, M.G., Muinelo-Romay, L., Pantel, K., Rossi, E., Terstappen, L., Wikman, H., Soria, J.-C., Farace, F.F., Renehan, A., Dive, C., Besse, B., Michiels, S.

Get full text

PB2099: A FIRST‐IN‐HUMAN PHASE 1 TRIAL OF NX‐1607, A FIRST‐IN‐CLASS ORAL CBL‐B INHIBITOR, IN PATIENTS WITH ADVANCED MALIGNANCIES INCLUDING RICHTER TRANSFORMATION DLBCL by Sharp, A., Williams, A., Blagden, S., Plummer, R., Hochhauser, D., Krebs, M. G., Pacey, S., Evans, J., Whelan, S., Nandakumar, S., Rogers, S., Jameson, K. L., Basile, F. G., Bono, J., Arkenau, H.‐T.

Get full text

EPIC: an evaluation of the psychological impact of early-phase clinical trials in cancer patients by Jittla, P., Graham, D.M., Zhou, C., Halliwell, J., O’Reilly, S., Aruketty, S., Azizi, A., Germetaki, T., Lowe, J., Little, M., Punnett, G., McMahon, P., Benson, L., Carter, L., Krebs, M.G., Thistlethwaite, F.C., Darlington, E., Yorke, J., Cook, N.

“…Anxiety and depression in patients with cancer is associated with decreased quality of life and increased morbidity and mortality. However, these are often…”
Get full text

1546PTreatment patterns and outcomes for patients (pts) with anaplastic lymphoma kinase-positive (ALK+) advanced non-small cell lung cancer (NSCLC) in US clinical practice by Krebs, M G, Polito, L, Smoljanović, V, Trinh, H, Crane, G

“…Abstract Background ALK inhibitors (ALKi) have shown substantial benefit in pts with advanced ALK+ NSCLC. We describe real-world treatment patterns and…”
Get full text

1551PBrain metastases, treatment patterns and outcomes in ROS1-positive NSCLC patients from US oncology community centers by Krebs, M G, Perez, L, Surinach, A, Doebele, R C, Martina, R, Martinec, M, Riehl, T, Meropol, N J, Wong, W, Crane, G

“…Abstract Background As new targeted therapies with CNS penetration and activity for non-small cell lung cancer (NSCLC) with ROS1 gene fusions (ROS1+) emerge,…”
Get full text

1576PEfficacy results of selective AXL inhibitor bemcentinib with pembrolizumab following chemo in patients with NSCLC by Trigo Perez, J M, Felip, E, Brunsvig, P, Helland, A, Viñolas, N, Ponce Aix, S, Carcereny Costa, E, Domine Gomez, M, Arriola, E, Garcia Campelo, R, Spicer, J, Thompson, J R, Ortega Granados, A L, Holt, R J, Lorens, J B, Shoaib, M, Siddiqui, A, Schmidt, E V, Chisamore, M J, Krebs, M G

“…Abstract Background The RTK AXL is implicated in epithelial-to-mesenchymal transition, negative regulation of anti-tumor immunity and resistance to multiple…”
Get full text

1191OPhase II study of olaparib (O) and durvalumab (D) (MEDIOLA): Updated results in patients (pts) with germline BRCA-mutated (gBRCAm) metastatic breast cancer (MBC) by Domchek, S, Postel-Vinay, S, Im, S-A, Park, Y H, Delord, J-P, Italiano, A, Alexandre, J, You, B, Bastian, S, Krebs, M G, Wang, D, Waqar, S, Lanasa, M, Angell, H K, Lai, Z, Gresty, C, Opincar, L M, Herbolsheimer, P, Kaufman, B

“…Abstract Background O (olaparib, Lynparza®) is approved for gBRCAm HER2(-) MBC based on the OlympiAD study. O-induced DNA damage may increase tumor antigen…”
Get full text

109OEntrectinib in locally advanced or metastatic ROS1 fusion-positive non-small cell lung cancer (NSCLC): Integrated analysis of ALKA-372-001, STARTRK-1 and STARTRK-2 by Barlesi, F, Drilon, A, Braud, F De, Cho, B C, Ahn, M J, Siena, S, Krebs, M G, Lin, C C, John, T, Tan, D S W, Seto, T, Dziadziuszko, R, Arkenau, H-T, Rolfo, C, Wolf, J, Ye, C, Riehl, T, Eng, S, Doebele, R C

Get full text

21OEPAC-Lung: Pooled analysis of circulating tumor cells in advanced non-small cell lung cancer by Lindsay, C R, Blackhall, F H, Carmel, A, Gazzaniga, P, Groen, H J M, Krebs, M G, Muinelo-Romay, L, Pantel, K, Rossi, E, Terstappen, L, Wikman, H, Soria, J-C, Farace, F F, Renehan, A, Dive, C, Besse, B, Michiels, S

Get full text

Terminal Modeling and Photocompensation of Complex Microcircuits by Pocock, D. N., Krebs, M. G.

“…Results are presented on generalized approaches to derive radiation-inclusive simplified models of linear and digital microcircuits. Application of the…”
Get full text